Semaglutide Side Effects: What the Clinical Evidence Actually Shows

What the STEP 1 trial recorded, and what it actually means for most people

The STEP 1 trial, published in the New England Journal of Medicine, is the bedrock of the Wegovy evidence base: 68 weeks, semaglutide 2.4 mg against placebo, in adults with obesity or overweight and at least one weight-related condition. Gastrointestinal events were the dominant side effect. Nausea, vomiting, diarrhoea and constipation were all more common in the semaglutide group than in those taking placebo, but the trial also found that most of these events were mild or moderate in severity and occurred mainly during the dose-escalation phase, not as a sustained feature of treatment.

Headache, fatigue and dizziness also appeared in the data, again predominantly in the early weeks. Injection-site reactions were recorded but uncommon. The pattern makes biological sense: semaglutide slows gastric emptying and acts on appetite centres in the brain, so the digestive system takes a little time to recalibrate. You can read the full NHS patient-level summary of what's known about semaglutide's effects on the NHS website, which maps neatly to what the trial found. For a broader look at semaglutide as a medicine, the semaglutide overview at nume covers the mechanism, the licence and the eligibility picture.

One practical note: the dose-escalation schedule used in the trial (moving up roughly every four weeks under prescriber supervision) exists partly to manage these early effects. The starting dose is a tolerability measure first and foremost. That context matters when reading headline side-effect rates.

The risks that need prompt medical attention

Beyond the common GI complaints, the evidence and regulatory guidance point to a smaller set of rarer but more serious concerns. Acute pancreatitis is the one the MHRA highlighted most recently: in its January 2026 Drug Safety Update for GLP-1 medicines, the regulator reminded prescribers and patients that severe, persistent stomach pain (especially if it radiates towards the back and may come with vomiting) warrants urgent medical assessment. The condition is infrequent, but serious when it occurs. Anyone on semaglutide who experiences that symptom pattern should not wait to see whether it passes.

Gallbladder problems, including gallstones, have also been reported with GLP-1 receptor agonists. Rapid weight loss of any kind can increase gallstone risk, and semaglutide-associated loss is often significant. Symptoms to watch: sharp pain in the upper right abdomen, pain spreading to the shoulder, nausea or fever accompanying that pain. Dehydration from prolonged vomiting or diarrhoea can put strain on the kidneys; staying well hydrated, especially in the early weeks, is important.

There is also a signal around mood: patients experiencing low mood, thoughts of self-harm or changes in mental wellbeing while on the medicine should contact their prescriber promptly. The less-discussed effects of semaglutide (covering these rarer concerns in more depth) is worth reading before starting. The MHRA Yellow Card scheme lets patients report any suspected side effect directly, which contributes to the ongoing safety monitoring of these medicines.

Managing side effects in practice, and when they don't settle

For most people, the early weeks are the hardest part. A few things consistently help: eating smaller portions at each meal rather than skipping food entirely, avoiding very fatty or heavily spiced dishes during the adjustment period, keeping water intake up, and not injecting on an empty stomach. These are common-sense adjustments, not clinical instructions, your prescriber and the Patient Information Leaflet are the right places for personal advice about managing your specific symptoms.

If nausea or vomiting is severe, if you're losing fluids faster than you can replace them, or if symptoms haven't eased after a couple of weeks at a stable dose, that's a conversation to have with your clinical team rather than something to push through alone. Dose escalation can sometimes be slowed to allow more adjustment time; that decision sits with the prescriber, not with the patient.

For anyone considering Wegovy and wanting to understand how the treatment works before looking at side effects, the Wegovy treatment page lays out what the medicine is and who it's licensed for. If you're comparing the side-effect profiles of different doses, the detail on individual strengths is covered on semaglutide 1 mg and semaglutide 2 mg context pages. Those curious about the broader semaglutide story (including both weight management and other clinical uses) will find the semaglutide side-chain explainer useful background.

Cost is occasionally a reason people don't raise concerns with their clinical team, particularly if they've sourced treatment from an unverified seller. The Wegovy price comparison page addresses what legitimate private treatment typically costs and why the pricing gap between reputable and unverified sources should itself be a red flag. The pen that arrives from a GPhC-registered pharmacy like nume comes in plain, unbranded packaging via DPD with a tracking link, if what you received looked nothing like that, it's worth questioning the source before continuing.

A clinician at our pharmacy reviews every consultation personally. If you have questions about whether semaglutide is suitable for you and how to manage the side effects, starting a free consultation is the right first step.